ClinicalTrials.gg
CompletedNCT04004962SYNOFRESHUpdated Aug 11, 2021

Use of Infrared Spectroscopy in Fast Septic Arthritis Diagnosis

An observational study in Joint Effusion, sponsored by Rennes University Hospital. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-11.

Sponsored by Rennes University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
360
Ages
18 Years and older
Sex
All
01

Study summary

To study the diagnostic performance of infrared spectroscopy on fresh synovial fluids in early septic arthritis diagnosis in patients with acute joint effusion

Read the detailed description

Diagnosis of a joint effusion is frequently a medical emergency, especially when septic arthritis is suspected. Septic arthritis diagnosis relies on microscopic and bacteriological analysis of synovial fluid obtained by arthrocentesis. Direct microscopic examination can be made within 2 to 12 hours but it is negative in about 50 % of the cases. It is necessary to wait 72 hours to obtain the result of the culture and reasonably rule out the diagnosis of septic arthritis. A method of establishing an immediate etiological diagnosis could improve the care of patients with joint effusion that is a therapeutic emergency and justify a hospitalization and a parenteral antibiotic therapy.

02

Conditions studied

  • Joint Effusion
03

In context

Lead sponsor

Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients over 18 year old
  • patients with an acute arthritis defined by an evolution of less than 6 weeks
  • patients benefiting from joint fluid puncture for diagnostic purposes in the rheumatology hospitals participating in the study
  • patients who received information about the protocol and have not expressed opposition to participate

Exclusion criteria

Exclusion Criteria:

  • patients opposing the study
  • protected major (safeguard justice, trusteeship and guardianship) and persons deprived of liberty
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
360 participants (actual)
Patient registry
No

Interventions

  • DeviceInfrared spectroscopy

    Infrared spectroscopy

06

What researchers measure

Primary outcomes

  1. Diagnosis of the cause of joint effusion

    The final diagnosis of the cause of joint effusion is made by the clinician based on the clinical and laboratory data : septic arthritis or other causes of arthritis

    Time frame: Up to 7 days (time to perform Spectroscopy and collect laboratory results)

Secondary outcomes

  1. Number of days of hospitalization

    The clinician will be asked to state how a positive or a negative result of the diagnostic test under study would have affected his decision to hospitalize the patient

    Time frame: Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)

  2. Total dose of antibiotics

    The clinician will be asked to state how a positive or a negative result of the diagnostic test under study would have affected his decision to start antibiotic therapy

    Time frame: Up to 2 months (time to collect data on hospitalization duration and antibiotic therapy duration)

07

Study locations

6 sites
  • CHU Angers
    Angers, 49933, France
  • CHRU Brest
    Brest, 29200, France
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
  • CHU Nantes
    Nantes, 44000, France
  • CHU de Rennes
    Rennes, 35033, France
  • CHRU Tours
    Tours, 37044, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in May 2021, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2019
First posted
Jul 2, 2019
StartActual
Sep 16, 2019
Primary completionActual
May 8, 2021
CompletionActual
May 8, 2021
Last update
Aug 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04004962
Responsible party
Sponsor
First posted
Jul 2, 2019
Start date
Sep 16, 2019
Primary completion
May 8, 2021
Completion
May 8, 2021
Last update
Aug 11, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion